Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 9/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ITGAL | P20701 | 1/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4589195 | 0.86 | TSHR (0.40) | HTTTMEM97FOLH1KMT2A | |
| SCHEMBL4589075 | 0.80 | TSHR (0.37) | HTTFOLH1ALDH1A1KMT2A | |
| SCHEMBL4587681 | 0.79 | FOLH1 (0.39) | HTTFOLH1ALDH1A1KMT2A | |
| SCHEMBL4587660 | 0.76 | TMEM97 (0.41) | TMEM97 | |
| SCHEMBL4587668 | 0.76 | TMEM97 (0.41) | TMEM97 | |
| SCHEMBL4586363 | 0.75 | TMEM97 (0.41) | TMEM97 | |
| SCHEMBL4586341 | 0.75 | TMEM97 (0.41) | TMEM97 | |
| SCHEMBL4589192 | 0.74 | TMEM97 (0.39) | TMEM97 | |
| SCHEMBL4588022 | 0.70 | TACR1 (0.35) | — | |
| SCHEMBL4588018 | 0.70 | TACR1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | PC, PDK1, NOS3 | HTT 4358/4885TMEM97 3841/4885RAB9A 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.